UNSPSC 51422365: Prednisolone sodium succinate

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H31O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8223RR9DWF, chemically known as 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-(hydrogen succinate) but more generally known as prednisolone sodium succinate, which bears US NIH Compound Identifier 4897. European Medicines Agency schedules Prednisolone sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04019MIG.

UNSPSC 51422365 Prednisolone sodium succinate is a Commodity code that nominally describes a specific corticosteroid pharmaceutical, but the recent state and local opportunities tagged under it show minimal alignment with that scope. The Seminole County, Florida IFB solicits naloxone and drug deactivation systems—emergency response supplies unrelated to prednisolone—while the Texas Health and Human Services Commission RFI explores direct-to-manufacturer prescription programs at a program-design level, not specific drug procurement. State and local governments buying under this code appear to be health departments, county health systems, and state pharmacy benefit programs, though the opportunities in the dataset do not substantiate consistent or frequent activity tied to prednisolone sodium succinate itself.

Geographic activity is limited to two states in the recent record: Florida and Texas. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) is a competitive bid for annual supply of naloxone and deactivation systems with quarterly deliveries to the Sanford health building; the Texas HHS RFI (HHS0017013, response deadline April 3, 2026) is exploratory market research on direct-to-manufacturer relationships for state pharmacy benefit programs, not a committed procurement. The code shows little relevant recent activity tied to its nominal pharmaceutical scope, suggesting either misclassification of these opportunities or sparse legitimate prednisolone-specific purchasing in state and local markets during this period.